Sera Prognostics, Inc.

NASDAQ:SERA

Medical - Diagnostics & Research

Healthcare
$1.91 -1.59%

-$0.03 today

Market cap
$74.11M
Beta
0.94
P/E (TTM)
-2.9
EPS (TTM)
-$0.64
52W Low $1.56High $4.09

Volume 0.01M

Average 0.06M

SERA Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Sera Prognostics, Inc.NASDAQ: SERA

Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026

Financing cash flow declines year over year

Q1 FY2026 financing cash flow of $20K fell 100.0% year over year, behind the -99.1% change in trailing-twelve-month financing cash flow. Sequentially, it fell 78.5% from the prior quarter. Over 3 fiscal years it compounded at +2110.8% a year.

Context

  • Financing cash flow amounted to 66698.8% of revenue in FY2025, up 63310.5 pp from a year earlier.
  • Financing cash flow increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -100.0% toward the trailing-twelve-month pace of -99.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$20K-78.5% QoQ
Last fiscal yearDec 2025
$54.03M+1970.8% YoY
LTMMar 2026
$504K-99.1% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year+1970.8%——
3-year CAGR+2110.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
54.03M USD
Year-over-year change
+1970.8%
4-year CAGR
-23.7%

Financing Cash Flow vs competitors

How SERA compares with its peers on the latest reported figures

  • Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -99.1% is the lowest of 8, against a peer median of +114.9%.
  • Financing cash flow amounts to 884.2% of revenue for SERA, versus a peer median of 519.7%.
SERA Competitors
Financing Cash Flow for SERA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STSSSkyAI, Inc.LTM Mar 2026$196.88M USD+891.4%+160.2%49605.2%
LUCDLucid Diagnostics Inc.LTM Mar 2026$49.08M USD+8.7%+182.8%955.9%
SRZNSurrozen, Inc.LTM Mar 2026$38.95M USD-57.9%—519.7%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$35.04M USD+172.3%+87.5%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$27.62M USD—+7.0%—
ONCYOncolytics Biotech Inc.LTM Mar 2026CA$23.71M CAD+114.9%+16.7%—
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$18.76M USD+4324.8%+205.6%54.6%
APYXApyx Medical CorporationLTM Mar 2026$9.64M USD+42.3%+253.4%17.2%
SERASera Prognostics, Inc.LTM Mar 2026$504K USD-99.1%+2110.8%884.2%
Peer median (excluding SERA) —+114.9%+160.2%519.7%

Competitors are the stored peer set for SERA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(35.01M)(44.19M)(36.24M)(32.9M)(31.93M)
Depreciation & Amortization659K756K900K833K940K
Deferred Income Tax00000
Stock-Based Compensation3.13M5.06M5.27M7.01M5.11M
Change in Working Capital(44K)3.55M3.52M11.28M(546K)
Accounts Receivables(3.14M)(2.97M)(5.36M)11.42M22K
Inventory00000
Accounts Payables603K352K(442K)455K(1.01M)
Other Working Capital2.49M6.17M9.32M(597K)441K
Other Non-Cash Items(372K)213K(638K)(412K)801K
Operating Cash Flow(31.64M)(34.61M)(27.19M)(14.19M)(25.62M)
Capital Expenditures(1.3M)(791K)(128K)(1.1M)(726K)
Acquisitions (Net)00000
Purchases of Investments(82.06M)(48.07M)(54.14M)(35.83M)(87.61M)
Sales of Investments800K54.4M54.4M48.68M59.84M
Other Investing Activities016K311K(1.05M)0
Investing Cash Flow(82.56M)5.55M438K11.74M(28.5M)
Debt Repayment(7.66M)(303K)(466K)(440K)(194K)
Common Stock Issued66.61M00054.22M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.66M308K1.22M3.05M0
Financing Cash Flow159.59M5K752K2.61M54.03M
Effect of Forex Changes00000
Net Change in Cash45.4M(29.05M)(26M)163K(99K)
Free Cash Flow(32.94M)(35.4M)(27.32M)(15.29M)(26.35M)

Sera Prognostics, Inc.

NASDAQ:SERA

Intrinsic Alpha fair value

Locked

Current Price

$1.91

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.